NASDAQ:GALT - Galectin Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 426.32 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.09 (-3.27%)

This chart shows the closing price for GALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galectin Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GALT

Analyst Price Target is $14.00
▲ +426.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galectin Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 426.32% upside from the last price of $2.66.

This chart shows the closing price for GALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Galectin Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2021HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00Low
8/13/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $12.00High
4/3/2020B. RileyReiterated RatingBuy$8.00 ➝ $4.00Medium
3/17/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $9.00High
3/7/2019B. RileyInitiated CoverageBuy$11.00Medium
2/13/2019B. RileyInitiated CoverageBuy ➝ Buy$11.00 ➝ $11.00High
8/16/2018HC WainwrightReiterated RatingBuy$12.00Low
5/15/2018HC WainwrightBoost Price TargetBuy$12.00High
1/4/2018Roth CapitalBoost Price TargetBuy$3.00 ➝ $8.00Medium
12/7/2017Roth CapitalLower Price TargetBuy$10.00 ➝ $3.00High
12/7/2017HC WainwrightReiterated RatingBuy$6.00 ➝ $10.00High
11/28/2017HC WainwrightBoost Price TargetBuy$3.50 ➝ $6.00High
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$8.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/A
4/3/2017(FBRC)Reiterated RatingMarket Perform$2.00Medium
3/30/2017HC WainwrightUpgradeNeutral ➝ Buy$3.50High
2/6/2017(FBRC)Reiterated RatingMarket Perform$2.00N/A
11/14/2016(FBRC)Set Price TargetHold$2.00N/A
10/3/2016(FBRC)DowngradeOutperform ➝ Market Perform$12.00 ➝ $2.00N/A
9/29/2016HC WainwrightDowngradeBuy ➝ Neutral$8.00 ➝ $1.50N/A
9/28/2016Roth CapitalReiterated RatingBuy ➝ Sell$3.00 ➝ $0.75N/A
8/26/2016(FBRC)Reiterated RatingBuyN/A
8/16/2016HC WainwrightReiterated RatingBuyN/A
8/11/2016(FBRC)Reiterated RatingBuy$12.00N/A
8/4/2016HC WainwrightReiterated RatingBuy$8.00N/A
(Data available from 7/24/2016 forward)
Galectin Therapeutics logo
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Read More

Today's Range

Now: $2.66
Low: $2.61
High: $2.78

50 Day Range

MA: $3.48
Low: $2.59
High: $4.44

52 Week Range

Now: $2.66
Low: $1.82
High: $5.70


255,741 shs

Average Volume

6,110,789 shs

Market Capitalization

$154.55 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Galectin Therapeutics?

The following equities research analysts have issued reports on Galectin Therapeutics in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for GALT.

What is the current price target for Galectin Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Galectin Therapeutics in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 426.3%. HC Wainwright has the highest price target set, predicting GALT will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Galectin Therapeutics in the next year.
View the latest price targets for GALT.

What is the current consensus analyst rating for Galectin Therapeutics?

Galectin Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GALT will outperform the market and that investors should add to their positions of Galectin Therapeutics.
View the latest ratings for GALT.

What other companies compete with Galectin Therapeutics?

How do I contact Galectin Therapeutics' investor relations team?

Galectin Therapeutics' physical mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company's listed phone number is 678-620-3186 and its investor relations email address is [email protected] The official website for Galectin Therapeutics is